Crucell and DSM Hit Pharmaceutical Technology Milestone

Percivia, a biotech research business jointly owned by biotech firm Crucell (Leiden, the Netherlands) and DSM, says it has significantly raised the yield of its mammalian cell-based technology for producing therapeutic proteins. From the latest test results Percivia says its PER.C6 human cell line, in conjunction with XD Technology generated a record yield of more than 27 grams/liter of therapeutic proteins. The increase compares with a yield in March of this year of just 15 grams/liter. This milstone was achieved using standard bioreactor equipment and readily...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers